Bruce Beesley, MD
Neurology · Albany, NYNPI 1215986765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,134 of the $2,446 with a category attached, or 87.2%. 14 manufacturers reported payments, led by Livanova USA, Inc. at 40.1% of the total. Reporting peaked in 2019 at $1,056 and has fallen 72.9% since, to $287 in 2025.
Across 95 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$981
- AbbVie$626
- Pfizer$186
- AstraZeneca$134
- Eisai Inc.$123
- Novartis$100
- plus $296 from 8 others
Across 1 payment — averaging $32,123 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$32K
What the payments were for
- Travel & lodging$31213%
- Food & beverage$2,13487%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 4 | $981 |
| AbbVie | 60 | $626 |
| Pfizer | 11 | $186 |
| AstraZeneca | 1 | $134 |
| Eisai Inc. | 1 | $123 |
| Novartis | 5 | $100 |
| Supernus Pharmaceuticals, Inc. | 2 | $69 |
| Lundbeck LLC | 2 | $51 |
| Bristol Myers Squibb | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| MDD US Operations, LLC | 2 | $29 |
| Biogen | 1 | $26 |
| Amgen | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$937
- ULTOMIRIS$134
- Leqembi$123
How this compares
$2,446 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $193,388 |
| UbrelvyUbrogepant | 31 | $38,048 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $29,956 |
| KeppraLevetiracetam | 14 | $19,981 |
| Emgality PenGalcanezumab-Gnlm | 18 | $17,408 |
| TopamaxTopiramate | 12 | $17,091 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $14,329 |
| DilantinPhenytoin Sodium Extended | 27 | $14,324 |
| Carbamazepine ErCarbamazepine | 50 | $13,985 |
| Depakote ErDivalproex Sodium | 12 | $13,611 |
| Gabapentin | 351 | $8,541 |
| Eletriptan HbrEletriptan Hydrobromide | 51 | $7,577 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 116 | $4,994 |
| Primidone | 87 | $4,492 |
| Pyridostigmine Bromide | 23 | $4,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $626 | $38,04831 claims |
| PfizerDilantin | $186 | $14,32427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.
Other neurology in Albany
- Charles ArgoffAlbany$1.2M
- Stanley PencAlbany$657K
- Angela ApplebeeAlbany$537K
- Krupa PandeyAlbany$433K
- Timothy LynchAlbany$265K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Stephen KriegerNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.